XOMA Royalty (XOMA) Other Non-Current Liabilities (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Other Non-Current Liabilities came in at $3.7 million in Q1 2026, up 12.0% year-on-year from $3.3 million in Q1 2025, and up 2.89% quarter-over-quarter from $3.6 million in Q4 2025.
XOMA Royalty (XOMA) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Other Non-Current Liabilities across 16 years of filings, most recently posting $3.7 million for Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $3.7 million, up 12.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 million (up 12.0% YoY), and the FY2025 annual result was $3.6 million, up 12.01% from the prior year.
- Other Non-Current Liabilities came in at $3.7 million for Q1 2026 at XOMA Royalty, up from $3.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $4.1 million in Q1 2023 to a low of $2.9 million in Q2 2024.
- The 4-year median for Other Non-Current Liabilities is $3.4 million (2025), against an average of $3.4 million.
- Peak annual rise in Other Non-Current Liabilities reached 16.43% in 2025, while the deepest fall reached 12.0% in 2025.
- XOMA Royalty's Other Non-Current Liabilities stood at $4.1 million in 2023, then retreated by 22.22% to $3.2 million in 2024, then advanced by 12.01% to $3.6 million in 2025, then rose by 2.89% to $3.7 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $3.7 million (Q1 2026), $3.6 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.70 Mn |
| Dec 31, 2025 | 3.60 Mn |
| Sep 30, 2025 | 3.50 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Mar 31, 2025 | 3.31 Mn |
| Dec 31, 2024 | 3.21 Mn |
| Sep 30, 2024 | 3.13 Mn |
| Jun 30, 2024 | 2.92 Mn |
| Mar 31, 2023 | 4.13 Mn |
| Sep 30, 2021 | 20,000.00 |
| Jun 30, 2021 | 20,000.00 |
| Mar 31, 2021 | 102,000.00 |
| Dec 31, 2020 | 50,000.00 |
| Sep 30, 2020 | 134,000.00 |
| Jun 30, 2020 | 35,000.00 |
| Mar 31, 2020 | 200,000.00 |
| Dec 31, 2019 | 43,000.00 |
| Sep 30, 2019 | 457,000.00 |
| Jun 30, 2019 | 294,000.00 |
| Mar 31, 2019 | 100,000.00 |